Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ARS Pharmaceuticals Inc SPRY

Healthcare Biotechnology
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and... see more

Recent & Breaking News (NDAQ:SPRY)

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile November 16, 2021

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HYZN, FB and SBTX

Accesswire November 16, 2021

SBTX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Silverback Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

Business Wire November 16, 2021

SBTX Lawsuit Filed: Jakubowitz Law Pursues Claims on Behalf of Silverback Therapeutics, Inc. Shareholders

Newsfile November 15, 2021

Silverback Deadline Alert

Newsfile November 15, 2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 - (SBTX)

Newsfile November 15, 2021

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile November 15, 2021

SBTX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 4, 2022 in the Class Action Filed on Behalf of Silverback Therapeutics, Inc. Limited Shareholders

Newsfile November 15, 2021

SBTX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Silverback Therapeutics, Inc.

Newsfile November 15, 2021

SBTX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 4, 2022 in the Class Action Filed on Behalf of Silverback Therapeutics, Inc. Limited Shareholders

Newsfile November 14, 2021

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Silverback To Contact Him Directly To Discuss Their Options

Newsfile November 14, 2021

LAWSUITS FILED AGAINST HYZN, FB and SBTX - Jakubowitz Law Pursues Shareholders Claims

Accesswire November 13, 2021

DEADLINE: Silverback Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SBTX

PR Newswire November 13, 2021

ALERT: Silverback Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SBTX

Newsfile November 13, 2021

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile November 12, 2021

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 - (SBTX)

Newsfile November 12, 2021

LAWSUITS FILED AGAINST SAM, EAR and SBTX - Jakubowitz Law Pursues Shareholders Claims

Accesswire November 12, 2021

CLASS ACTION UPDATE for SAM, HEPS and SBTX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Accesswire November 12, 2021

Silverback Therapeutics Presents SBT6050-201 Trial in Progress Poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Business Wire November 12, 2021

Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021

Business Wire November 12, 2021